Predictive value of clinical judgment of tumour progression in phase II trials.
<h4>Background</h4>The diagnosis of tumour progression or progressive disease (PD) is a key element for designing and interpreting contemporary phase II trials. In some cases, PD is stated by the physician and is not formally confirmed by imaging.<h4>Purpose</h4>In this study...
Guardado en:
Autores principales: | Nuria Kotecki, Nicolas Penel, Antoine Adenis, Charles Ferte, Stéphanie Clisant |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3863f9b65184415893c32d5361af0b0c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
por: Charles Ferte, et al.
Publicado: (2011) -
Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
por: Nicolas Penel, et al.
Publicado: (2009) -
Neural underpinnings of morality judgment and moral aesthetic judgment
por: Qiuping Cheng, et al.
Publicado: (2021) -
Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
por: Monika Michałowska, et al.
Publicado: (2014) -
Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
por: Shuyun Pang, et al.
Publicado: (2021)